New Classifications of Five Distinct “Sleep” Profi... ...
A Professional Overview of Hypertension ...
High-speed imaging tracks live brain cell activity...
Drug candidate slows motor neuron disease progress...
Drug candidate slows motor neuron disease progress...
Mark Cuban: A Master Disrupter for American Health...
Superbugs on your plate: How antimicrobial resistance spread...
June 13,2026
Can marijuana cause lung cancer?...
June 12,2026
Standard depression screening could be missing key symptoms ...
June 11,2026
More women are having babies later in life. How to improve y...
June 10,2026
For severe babesiosis, red blood cell exchange is associated...
June 09,2026
Cause or effect? Study answers question about gene linked wi...
June 08,2026
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
Eye Infections (Updated) | Clinical Medicine...
Announcement of the 2025 Nobel Prize in ...
Dr. Fauci among hundreds who've contract...
Why are young, healthy adults experienci...
Reprogramming Stem Cells Could Cure Type...
More News
UTHealth Houston study to examine how eviction protection during the pandemic affects mental health

UTHealth Houston study to examine how eviction protection during the pandemic affects mental health

During the COVID-19 pandemic, eviction moratoria prevented or delayed many people from experiencing homelessness. But now that the pandemic is over and the short-term eviction protection has ended, th
World medicine November 07,2023
UTHealth Houston study to examine how eviction protection during the pandemic affects mental health

UTHealth Houston study to examine how eviction protection during the pandemic affects mental health

During the COVID-19 pandemic, eviction moratoria prevented or delayed many people from experiencing homelessness. But now that the pandemic is over and the short-term eviction protection has ended, th
World medicine November 07,2023
mRNA-4157 Plus Pembrolizumab Under Further Investigation in Phase 3 Trial in High-Risk Melanoma

mRNA-4157 Plus Pembrolizumab Under Further Investigation in Phase 3 Trial in High-Risk Melanoma

The combination of mRNA-4157 (V940) and pembrolizumab (Keytruda) will be further evaluated as an adjuvant treatment option for patients with resected, high-risk, stage IIB to IV melanoma in the phase
World medicine November 07,2023
mRNA-4157 Plus Pembrolizumab Under Further Investigation in Phase 3 Trial in High-Risk Melanoma

mRNA-4157 Plus Pembrolizumab Under Further Investigation in Phase 3 Trial in High-Risk Melanoma

The combination of mRNA-4157 (V940) and pembrolizumab (Keytruda) will be further evaluated as an adjuvant treatment option for patients with resected, high-risk, stage IIB to IV melanoma in the phase
World medicine November 07,2023
Butterfly-inspired imaging sensor can detect cancer cells with high accuracy

Butterfly-inspired imaging sensor can detect cancer cells with high accuracy

There are many creatures on our planet with more advanced senses than humans. Turtles can sense Earth's magnetic field. Mantis shrimp can detect polarized light. Elephants can hear much lower freq
World medicine November 07,2023
Butterfly-inspired imaging sensor can detect cancer cells with high accuracy

Butterfly-inspired imaging sensor can detect cancer cells with high accuracy

There are many creatures on our planet with more advanced senses than humans. Turtles can sense Earth's magnetic field. Mantis shrimp can detect polarized light. Elephants can hear much lower freq
World medicine November 07,2023
Kirtane Highlights Uniqueness of Solid Tumor CAR T-Cell Agent A2B530

Kirtane Highlights Uniqueness of Solid Tumor CAR T-Cell Agent A2B530

For patients with solid tumors, investigators have faced hurdles replicating successes with chimeric antigen receptor (CAR) T-cell therapies. The novel CAR T-cell agent A2B530, looks to forge a pathwa
World medicine November 07,2023
Kirtane Highlights Uniqueness of Solid Tumor CAR T-Cell Agent A2B530

Kirtane Highlights Uniqueness of Solid Tumor CAR T-Cell Agent A2B530

For patients with solid tumors, investigators have faced hurdles replicating successes with chimeric antigen receptor (CAR) T-cell therapies. The novel CAR T-cell agent A2B530, looks to forge a pathwa
World medicine November 07,2023
From Mount Everest to your liver: The alarming reach of 'forever chemicals' in our environment and health

From Mount Everest to your liver: The alarming reach of 'forever chemicals' in our environment and health

In a recent review published in the journalScience of The Total Environment,researchers collate and discuss available literature on per- and polyfluoroalkyl substances (PFAS). They highlig
World medicine November 07,2023
From Mount Everest to your liver: The alarming reach of 'forever chemicals' in our environment and health

From Mount Everest to your liver: The alarming reach of 'forever chemicals' in our environment and health

In a recent review published in the journalScience of The Total Environment,researchers collate and discuss available literature on per- and polyfluoroalkyl substances (PFAS). They highlig
World medicine November 07,2023
INDIGO Trial Supports Vorasidenib as Effective Targeted Therapeutic in IDH1/2+ Low-Grade Glioma

INDIGO Trial Supports Vorasidenib as Effective Targeted Therapeutic in IDH1/2+ Low-Grade Glioma

Practice-changing safety and efficacy findings from the phase 3 INDIGO trial (NCT04164901) underscore the value of adding vorasidenib (AG-881) to the treatment armamentarium inIDH1/2-mutant glio
World medicine November 07,2023
INDIGO Trial Supports Vorasidenib as Effective Targeted Therapeutic in IDH1/2+ Low-Grade Glioma

INDIGO Trial Supports Vorasidenib as Effective Targeted Therapeutic in IDH1/2+ Low-Grade Glioma

Practice-changing safety and efficacy findings from the phase 3 INDIGO trial (NCT04164901) underscore the value of adding vorasidenib (AG-881) to the treatment armamentarium inIDH1/2-mutant glio
World medicine November 07,2023
Herrera Spotlights Key Research Across Hematologic Malignancies From the 2023 ASCO Annual Meeting

Herrera Spotlights Key Research Across Hematologic Malignancies From the 2023 ASCO Annual Meeting

Positive findings from thephase 3 SWOG S1826 trial(NCT03907488) have set the stage for ongoing efforts to align the treatment of adult and pediatric patients with newly diagnosed stage III
World medicine November 07,2023
Herrera Spotlights Key Research Across Hematologic Malignancies From the 2023 ASCO Annual Meeting

Herrera Spotlights Key Research Across Hematologic Malignancies From the 2023 ASCO Annual Meeting

Positive findings from thephase 3 SWOG S1826 trial(NCT03907488) have set the stage for ongoing efforts to align the treatment of adult and pediatric patients with newly diagnosed stage III
World medicine November 07,2023
AI-assisted smartphone app performs well in skin cancer diagnosis

AI-assisted smartphone app performs well in skin cancer diagnosis

Artificial intelligence (AI) is already widely used in medical diagnostics. An Austrian-Australian research team led by dermatologist Harald Kittler from MedUni Vienna investigated the extent to which
World medicine November 07,2023
AI-assisted smartphone app performs well in skin cancer diagnosis

AI-assisted smartphone app performs well in skin cancer diagnosis

Artificial intelligence (AI) is already widely used in medical diagnostics. An Austrian-Australian research team led by dermatologist Harald Kittler from MedUni Vienna investigated the extent to which
World medicine November 07,2023
FDA approves cord blood stem cell product for blood cancer patients

FDA approves cord blood stem cell product for blood cancer patients

The U.S. Food and Drug Administration approved Omisirge (omidubicel-onlv), a substantially modified allogeneic cord blood-based cell therapy, to cut the risk of infection in patients with blood cancer
World medicine November 07,2023
FDA approves cord blood stem cell product for blood cancer patients

FDA approves cord blood stem cell product for blood cancer patients

The U.S. Food and Drug Administration approved Omisirge (omidubicel-onlv), a substantially modified allogeneic cord blood-based cell therapy, to cut the risk of infection in patients with blood cancer
World medicine November 07,2023
FDA Accepts sBLA for Zanubrutinib Plus Obinutuzumab for R/R Follicular Lymphoma

FDA Accepts sBLA for Zanubrutinib Plus Obinutuzumab for R/R Follicular Lymphoma

The FDA has accepted a supplemental biologics license application (sBLA) seeking the approval of zanubrutinib (Brukinsa) in combination with obinutuzumab (Gazyva) in the treatment of adult patients wi
World medicine November 07,2023
FDA Accepts sBLA for Zanubrutinib Plus Obinutuzumab for R/R Follicular Lymphoma

FDA Accepts sBLA for Zanubrutinib Plus Obinutuzumab for R/R Follicular Lymphoma

The FDA has accepted a supplemental biologics license application (sBLA) seeking the approval of zanubrutinib (Brukinsa) in combination with obinutuzumab (Gazyva) in the treatment of adult patients wi
World medicine November 07,2023
More News
Week’s Top
Podcasts
... Preparing for a tough exam? A tough gym workout could help with your studies ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... Brain activity goes to extremes in soccer fans, neuroimaging reveals ...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com